Aims of these analyses were to ( @ ) develop a population pharmacokinetic-pharmacodynamic model for describing the relationship between axitinib exposure and changes in diastolic BP ( dBP ) and ( @ ) simulate changes in dBP with different axitinib dosing regimens .